Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 29,083 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: dose level 1 Clear all

Conditions: Rectal Cancer
Interventions: Sorafenib, 5-Fluorouracil (5-FU), Radiation; Drug · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer
Interventions: Rucaparib; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: aldesleukin, filgrastim, natural killer cell (NK) therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, Umbilical Cord Blood Transplantation (UCBT), Total body irradiation (TBI); Biological · Drug · Procedure + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 45 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Prostate Cancer
Interventions: Androgen deprivation therapy (ADT), Brachytherapy, Hypofractionated pelvic External beam radiation; Biological · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Hypertension
Interventions: Irbesartan and Hydrochlorothiazide, Avalide; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)
Interventions: LY3410738, Venetoclax, Azacitidine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 12
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 8 more

Conditions: Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Myeloproliferative Disease, Chronic Myeloid Leukemia
Interventions: rigosertib; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma, Advanced Leiomyosarcoma, Leiomyosarcoma Metastatic
Interventions: Lurbinectedin, Doxorubicin; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 6
States / cities: Phoenix, Arizona • Jacksonville, Florida • Boston, Massachusetts + 2 more

Conditions: Advanced Non Small Cell Lung Cancer
Interventions: Part A - AZD9291 in combination with AZD6094, Part A - AZD9291 in combination with continuous selumetinib (Asian subjects), Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects), Part A - AZD9291 in combination with intermittent selumetinib, Part A - AZD9291 in combination with MEDI4736, Part B - AZD9291 in combination with AZD6094, Part B - AZD9291 in combination with selumetinib, Part B - AZD9291 in combination with MEDI4736, Part C - AZD6094 monotherapy (Japan only), Part C - AZD9291 in combination with AZD6094 (Japan only), Part D - AZD9291 in combination with AZD6094; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 6
States / cities: Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more

Conditions: Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Interventions: REL-1017, Placebo; Drug
Lead sponsor: Relmada Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 10
States / cities: Little Rock, Arkansas • Garden Grove, California • San Diego, California + 7 more

Conditions: Healthy Volunteer
Interventions: Tavapadon; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Relapsing Multiple Sclerosis
Interventions: Teriflunomide, Evobrutinib; Drug
Lead sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 51
States / cities: Mobile, Alabama • Phoenix, Arizona • Long Beach, California + 44 more

Conditions: Healthy
Interventions: AC-1202, AC-SD-01 (50 g), AC-SD-01 (75 g); Drug
Lead sponsor: Cerecin; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Volunteers
Interventions: Acalabrutinib, Microtracer [14C]ACP-196; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: HIV Infections
Interventions: BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted, Placebo; Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 51 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • New York, New York

Conditions: Tuberculosis, Tuberculosis, Pulmonary
Interventions: TBI-223 oral suspension, TBI-223 enteric capsule, TBI-223 SR Tablet Prototype 1, TBI-223 SR Tablet Prototype 2, TBI-223 SR Tablet Prototype 3, TBI-223 IR Tablet, Placebo suspension; Drug
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hypophosphatemia, Familial, Hyperparathyroidism
Interventions: Paricalcitol, Placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 9 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hodgkin's Lymphoma, Multiple Myeloma, Non-Hodgkin's Lymphoma
Interventions: Nestle Impact Advanced Recovery; Dietary Supplement
Lead sponsor: Greg Monohan; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Colorectal Neoplasms, Gastrointestinal Neoplasms
Interventions: JNJ-89402638, Bevacizumab, FOLFOX, FOLFIRI; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Tucson, Arizona • Aurora, Colorado • Sarasota, Florida + 3 more

Conditions: Metastatic Breast Cancer
Interventions: Bevacizumab, Placebo, Chemotherapy; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 5
States / cities: Fullerton, California • Santa Barbara, California • Iowa City, Iowa + 2 more

Conditions: Healthy Volunteers
Interventions: TAK-227; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Advanced Renal Cell Carcinoma (RCC)
Interventions: Pumitamig, Ipilimumab, Cabozantinib, Casdatifan; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 17
States / cities: Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more

Conditions: Lymphoma, Acute Lymphoblastic Leukemia
Interventions: Apixaban, No systemic anticoagulant prophylaxis; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 64
States / cities: Phoenix, Arizona • Duarte, California • Loma Linda, California + 56 more

Conditions: Pleural Mesothelioma
Interventions: Doxorubicin, Cisplatin, Pemetrexed, Radiotherapy; Drug · Radiation
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer

Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer

Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted Conditions

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)

Lurbinectedin + Doxorubicin In Leiomyosarcoma

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD

A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants

Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

Study to Compare the Pharmacokinetics of AC 1202 and Two Doses of AC-SD-01 on Ketone Body Production

A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants

A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 Gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults

Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets

Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)

A Study of TAK-227 in Healthy Adults

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

Trimodal Lung-Sparing Treatment of Pleural Mesothelioma